Welcome to our dedicated page for Context Therapeutics news (Ticker: CNTX), a resource for investors and traders seeking the latest updates and insights on Context Therapeutics stock.
Context Therapeutics Inc. reports developments as a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors. Its news centers on oncology programs including CTIM-76, a CLDN6 x CD3 bispecific antibody; CT-95, a MSLN x CD3 bispecific antibody; and CT-202, a Nectin-4 x CD3 bispecific antibody.
Recurring updates cover clinical and preclinical data, regulatory designations, scientific conference presentations, operating results, research and development spending, liquidity, investor-conference activity and equity-based employee inducement grants. CTIM-76 has received FDA Fast Track designation for platinum-resistant ovarian cancer, adding regulatory status to the company's solid-tumor development disclosures.
Context Therapeutics (Nasdaq: CNTX) announced a poster presentation at the American Association for Cancer Research Annual Meeting 2026, April 17-22 in San Diego. The poster will present preclinical data on CT-202, a Nectin-4 x CD3 T cell engaging bispecific antibody for solid tumors.
The poster (Abstract #5392) is scheduled for Tuesday, April 21, 2026, 9:00 a.m.–12:00 p.m. PT in Poster Section 48, Session PO.CL05.12. According to the company, the poster will be available on its Publications page at the start of the session.
Context Therapeutics (Nasdaq: CNTX) will participate in multiple investor conferences in February–March 2026, presenting at Guggenheim, TD Cowen, Citizens, and Leerink events.
Presentations, fireside chats, and 1x1 meetings are scheduled; a live webcast will be available on the company's News and Events page with replays for 90 days.
Context Therapeutics (Nasdaq:CNTX) granted non-qualified stock options totaling 120,000 shares to two new employees as inducement awards under Nasdaq Listing Rule 5635(c)(4).
The options were granted on hire dates (January 1, 2026 and January 12, 2026) with exercise prices equal to the Nasdaq closing prices on those dates ($1.47 and $1.49). Each option has a 10-year term and vests over four years: 25% after one year and the remainder in 36 equal monthly installments, subject to continued service.
Context Therapeutics (Nasdaq: CNTX) presented posters on its CT-95 and CT-202 bispecific T cell engager programs at the SITC 40th Annual Meeting (Nov 7–9, 2025).
CT-95 (mesothelin x CD3) is avidity enhanced and affinity tuned; as of the Oct 30, 2025 cutoff the Phase 1 trial has enrolled 6 patients and is dosing Cohort 3 (priming 0.18 µg/kg, full dose 0.6 µg/kg). No cytokine release syndrome > Grade 2, no dose limiting toxicities, and no MTD reached; initial Phase 1a data is anticipated in mid-2026.
CT-202 (nectin-4 x CD3) shows potent preclinical activity with favorable PK/safety and the company expects to complete regulatory filings to support a first-in-human trial in Q2 2026. Presentation materials will be posted in the company’s Publications and Posters section.
Context Therapeutics (Nasdaq: CNTX) reported third-quarter 2025 results and a clinical update on its T cell engager pipeline. As of September 30, 2025, cash and cash equivalents were $76.9 million and the company expects runway into 2027. The company reported a Q3 2025 net loss of $9.7 million versus $17.5 million in Q3 2024 and R&D expense of $8.7 million versus $16.8 million a year earlier, driven largely by lower CT-202 and CT-95 spend.
Clinical highlights: CTIM-76 (CLDN6 x CD3) has enrolled 12 patients (cutoff Oct 30, 2025), shows preliminary RECIST responses beginning in Cohort 3, no CRS > Grade 1, no DLT, and MTD not reached; updated Phase 1a/Phase 1b dose selection expected Q2 2026. CT-95 (MSLN x CD3) has enrolled 6 patients, is in Cohort 3 with target exposure projected at Cohort 4, no DLT, and no CRS > Grade 2; initial Phase 1a data expected mid-2026. CT-202 remains preclinical with planned filings toward a first-in-human trial in Q2 2026.
Context Therapeutics (Nasdaq: CNTX) will participate in two investor conferences in November 2025: the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston (Nov 10-12) and the Stifel 2025 Healthcare Conference in New York (Nov 11-13).
At Guggenheim, Context will hold a fireside chat on Nov 10 at 3:00 PM ET plus 1x1 meetings the same day. At Stifel, Context will present on Nov 12 at 10:00 AM ET and hold 1x1 meetings on Nov 12. A live webcast of the presentation will be available on the company website and replays will be posted for 90 days.
For meeting requests, contact your conference representative or IR@contexttherapeutics.com.
Context Therapeutics (NASDAQ:CNTX) will present two poster presentations at the Society for Immunotherapy of Cancer 40th Annual Meeting, November 7–9, 2025, in National Harbor, MD.
One poster is a Trial in Progress for the Phase 1, first‑in‑human study of CT-95 (mesothelin x CD3 TCE) in advanced solid tumors (Abstract #586), scheduled Saturday, November 8, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls. The second poster covers preclinical efficacy, safety, and PK data for CT-202 (Nectin-4 x CD3 TCE) (Abstract #963), scheduled Friday, November 7, 2025 at 10:00 AM ET in Prince George ABC Exhibit Halls.
Abstracts are available via the SITC 40th Annual Meeting website.
Context Therapeutics (Nasdaq: CNTX) granted a non-qualified stock option inducement to a new employee on October 1, 2025 under Nasdaq Listing Rule 5635(c)(4). The award covers 30,000 shares with an exercise price of $0.97 per share (Nasdaq closing price on the grant date). Options have a 10‑year term and vest over 4 years: 25% on the first anniversary and the remaining 75% in 36 equal monthly installments, subject to continued service. The grant was made outside the company’s 2021 Long‑Term Performance Incentive Plan as permitted by Nasdaq rule as an inducement for employment.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company focused on developing T cell engaging bispecific antibodies for solid tumors, has announced its participation in two upcoming investor conferences.
The company will present at the Cantor Global Healthcare Conference 2025 on September 3 with a fireside chat at 10:55 AM ET, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8 with a fireside chat at 3:30 PM ET. Both events will be held in New York, NY and include one-on-one meeting opportunities with management.
Context Therapeutics (Nasdaq: CNTX), a clinical-stage biopharmaceutical company, reported Q2 2025 financial results and pipeline updates. The company maintains a strong financial position with $83.5 million in cash, expected to fund operations into 2027. Context is advancing two key clinical programs: CTIM-76 (CLDN6 x CD3 bispecific antibody) and CT-95 (MSLN x CD3 bispecific antibody), with initial data expected in 2026.
The company reported a net loss of $8.8 million for Q2 2025, with R&D expenses increasing to $7.8 million compared to $1.4 million in Q2 2024. Notable developments include the first patient dosed in the CT-95 Phase 1 trial and the appointment of Dr. Karen Chagin as Chief Medical Officer.